IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRADIMED CORPORATION for the event date of June 10, 2016. The filing addresses a material definitive agreement regarding executive compensation adjustments.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a non-cash accounting adjustment related to equity awards.
Material Changes
On June 10, 2016, the Board of Directors modified the vesting terms for options and restricted stock units previously granted to Jim Hawkins. Although Mr. Hawkins departed from the Board, the Board decided to continue the vesting period for these awards in recognition of his continuing advice. Under ASC 505 and 718, this action is accounted for as a modification, which will result in incremental expense.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The primary contingency noted is the accounting impact of the equity award modification, which will increase expenses.
Key Facts for Investor Verification
- The Board extended the vesting schedule for Jim Hawkins' equity awards despite his departure from the Board.
- This modification will trigger incremental compensation expense under ASC 505 and 718.
- No financial performance data or operational metrics are disclosed in this specific filing.